OncoSil FDA HDE Application Reaches Final Review as TRIPP-FFX Hits Endpoints

OncoSil Medical (ASX: OSL) says its US Humanitarian Device Exemption (HDE) application for distal cholangiocarcinoma has cleared all substantive questions from the US Food and Drug Administration and moved into the agency’s final review stage.

That is the lead development from a pair of price-sensitive updates released together, with the second showing positive clinical data from the company’s TRIPP-FFX study in pancreatic cancer.

OncoSil is a medical device that delivers phosphorus-32 microparticles directly into tumours. In the pancreatic setting, the company has described it as being used alongside chemotherapy for unresectable locally advanced pancreatic cancer.

The company is seeking an HDE for use in distal cholangiocarcinoma (dCCA), a rare bile duct cancer indication.

OncoSil said this is the most advanced point reached so far by its US regulatory program.

While approval has not been granted and the company’s wording remains conditional, the FDA has confirmed that all outstanding questions have been satisfactorily addressed.

The HDE pathway applies to rare conditions affecting fewer than 8,000 people a year in the US, a threshold underpinning OncoSil's dCCA application.

The company also said average life expectancy without treatment for dCCA is about six months, setting out the clinical context for the indication.

What the FDA Still Wants

The remaining FDA request is narrower than the earlier review phase, with the agency seeking final device labelling and any modifications or updates to post-market study plans.

OncoSil said it has 30 days from the correspondence to submit that material, and the FDA intends to complete its review within 45 days of the final submission.

That leaves a more defined near-term timetable than investors had before the announcement, but it is still not automatic.

The final step may look administrative, yet timing still depends on the company lodging complete materials and on the FDA accepting any final labelling or post-market study requirements.

TRIPP-FFX Hits Main Endpoints

The company also made an announcement concerning TRIPP-FFX, an open-label, multi-centre, randomised, non-comparative study in unresectable locally advanced pancreatic cancer.

The study tested OncoSil added to standard-of-care FOLFIRINOX, a chemotherapy regimen already widely used in this disease setting.

The result matters because OncoSil is already pursuing multiple regulatory pathways around how its device can be used alongside chemotherapy in different jurisdictions.

OncoSil said TRIPP-FFX met both co-primary endpoints. Those were safety and tolerability, and Local Disease Control Rate at 16 weeks.

Investigators concluded that adding OncoSil to FOLFIRINOX resulted in limited and manageable toxicities, according to the company.

At the same time, the trial design places limits on how far the data can be taken because the study was randomised but non-comparative, and it was not powered for direct arm-to-arm statistical comparisons.

A total of 88 patients were randomised, with 43 assigned to FOLFIRINOX and 45 assigned to FOLFIRINOX + OncoSil in the intention-to-treat population.

What to Watch

The nearest milestone is practical rather than theoretical: whether OncoSil submits the final labelling package and any post-market study updates inside the 30-day FDA window, and whether the agency then adheres to its stated 45-day review timetable.

On the clinical side, the next question is how regulators and clinicians interpret TRIPP-FFX.

The trial met its co-primary endpoints, but it was also randomised and non-comparative, with no power for direct statistical arm-to-arm claims.

Funding and execution also remain part of the story.

In its 1H FY26 accounts, OncoSil reported cash and cash equivalents of $2.85 million at 31 December 2025, a loss after tax of $4.53 million, and net operating cash outflow of $6.96 million.

Against that, the company had disclosed an approximately $8.0 million capital raise and a $1.84 million R&D tax incentive refund.

Commercial conversion is the broader follow-through issue.

Earlier filings pointed to record dose sales, first treatments in several European markets, and manufacturing progress at a new Sydney facility in Macquarie Park in partnership with Cyclotek.

The next phase is whether regulatory gains translate into sustained procedure volumes under those different market settings.